Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

261
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes Care and Biopharmaceuticals segments.

The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity.

The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Number of employees : 40 957 persons.
Sales per Businesses
20132014Delta
DKK (in Million)%DKK (in Million)%
Diabetes Care65,45678.3%69,98078.8% +6.46%
Biopharmaceuticals18,11621.7%18,82621.2% +3.77%
Assets Not Allocated to Business-----
Sales per Regions
20132014Delta
DKK (in Million)%DKK (in Million)%
North America39,02446.7%43,12348.6% +9.51%
Europe20,06324%20,15022.7% +0.43%
International12,00714.4%12,54014.1% +4.25%
Region China7,1618.6%8,0889.1% +11.46%
Japan & Korea5,3176.4%4,9055.5% -8.4%
Managers
NameAgeSinceTitle
Lars Rebien Sørensen611982Chief Executive Officer
Kåre Schultz541989President & Chief Operating Officer
Göran Ando662005Chairman
Jesper Brandgaard, MBA521999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD551991Chief Science Officer & Executive Vice President
Kristina Lee--Vice President-Strategic Research & Development
Alan C. Moses, MD-2008Global Chief Medical Officer
Anne Marie Handrup Kverneland591981Director
Stig Strøbæk511992Director
Bruno Francois Jules Angelici, MBA682011Independent Non-Executive Director
Shareholders
NameShares%
Novo Nordisk Fonden 163,814,000 7.94%
Capital Research & Management Co. (World Investors) 162,931,176 7.90%
Elo Mutual Pension Insurance Co. 85,497,685 4.15%
Norges Bank Investment Management 38,744,319 1.88%
The Vanguard Group, Inc. 31,335,859 1.52%
Northern Cross LLC 28,714,578 1.39%
Carmignac Gestion SA 25,979,520 1.26%
Novo Nordisk A/S 21,991,691 1.07%
BlackRock Investment Management (UK) Ltd. 20,227,931 0.98%
Alecta Pension Insurance Mutual 18,325,000 0.89%
Holdings
NameShares%Valuation
Novo Nordisk A/S (NOVO.B) 21,991,6911.07%1,250,488,455 USD
Nnit A/S (NNIT) 6,375,00025.5%149,324,303 USD
Innate Pharma (IPH) 5,422,70810.2%95,095,915 USD
Pieris Pharmaceuticals, Inc. 2,051,8026.97%6,155,406 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
NOVARTIS AG
ROCHE HOLDING LTD..
PFIZER INC.
MERCK & CO., INC.
SANOFI
ACTAVIS PLC
BAYER AG
NOVO NORDISK A/S
BRISTOL-MYERS SQU..
GLAXOSMITHKLINE P..
ELI LILLY AND CO
VALEANT PHARMACEU..
ABBOTT LABORATORI..
TEVA PHARMACEUTIC..
REGENERON PHARMAC..
SHIRE PLC
TAKEDA PHARMACEUT..
MYLAN NV
CSL LIMITED
Sector Pharmaceuticals
Novo Nordisk A/S : Connections
Novo Nordisk Holding Ltd.
Symphogen A/S
Novo Nordisk Pharmaceuticals A/S
Essex Bidco Ltd.
Archimedes Pharma UK Ltd.
Novo A/S
Novo Nordisk Region China A/S
Bio*One Capital Pte Ltd.
Steno Diabetes Center A/S
EUSA Pharma (Europe) Ltd.
Bertelsmann Management SE
RAND Health
Novo Nordisk Gsc Holding A/S
Essex Woodlands Health Ventures UK Ltd.
Novo Nordisk Invest 2 A/S
SWMF Life Science Venture Fund LP
Novo Nordisk Region North America Ii A/S
Novo Nordisk China Pharmaceuticals Co. Ltd.
American College of Physicians
University of Copenhagen
Novo Nordisk Region Japan & Korea A/S
New England Healthcare Institute
Novo Nordisk Region Europe A/S
Novo Nordisk Fonden
LEGO A/S
Danmarks Nationalbank
Novo Nordisk Region International Operations A/S
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd
Gladsaxe, Capital Region 2880

Phone : +45.44.44.88.88
Fax : +45.44.49.05.55
Web : www.novonordisk.com
© 2015 People , Fundamentals and Ownership